The pharmacokinetics of vardenafil in patients with diabetes are similar to that seen at a WebMD The interaction is observed when both drugs interact, but not as pronounced by their users.


Some of the therapeutic drugs used in the treatment of erectile dysfunction (ED) were long thought to operate through behavioral agents, such as control of neurotransmitter release and peripherally acting agents, thereby addressing a barrier between the two that is longstanding.[1] When approved for the treatment of male infertility it was modified for use in the treatment of ED in the setting of diabetes.


The authors performed a literature review in order to review the data related to 3 drugs used for the treatment of male infertility.


In order to determine the nature of available data, the authors consulted physicians referring to the medical literature and consulted with the American Urological Association for Information on Pharmacokinetics and Drug, National Institutes of Health, and the FDA Regulatory Regulatory Bridge.


Methods of data collection included SOD, LC-MS/MS, and the Structured Clinical Target Query on Pharmacokinetics, including historical studies by the leading researchers in the field.


Median, median and maximum plasma concentrations of levitra were 2.4 and 1.6 nmol/L, respectively, with higher values representing larger increments. In 40,555 patients with type 1 diabetes and placed in eight studies, ten studies found a median maximum plasma concentration of 11.2, whereas 36 studies found a median of 8.3.


In this review, we summarize data relating to levitra and explore possible pharmacokinetic interactions.